GlassScriptPhysician profile
Stephen R Barter
NPI 1689779092
$6,176.47
in general payments reported to CMS, 2019-2025
27 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $530 · 2021: $643 · 2022: $1,004 · 2023: $963 · 2024: $999 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,637.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $984.99 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $620.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $554.50 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $416.15 | 2019-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $301.29 | 2019-2022 | |
| Lilly USA, LLC | $260.12 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $236.34 | 2020-2024 | Trintellix |
| Abbott Laboratories | $177.21 | 2022-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $176.59 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $153.48 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.20 | 2019-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $73.67 | 2022-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $63.06 | 2025 | Auvelity |
| Amgen INC. | $47.12 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $46.48 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $40.83 | 2024 | Camzyos |
| Collegium Pharmaceutical, INC. | $39.49 | 2025 | Xtampza |
| Bayer Healthcare Pharmaceuticals INC. | $37.20 | 2022-2023 | |
| Astellas Pharma US INC | $36.41 | 2023-2024 | Veozah |
| Dexcom, INC. | $33.74 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $32.40 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.30 | 2022 | |
| Corcept Therapeutics | $24.86 | 2024 | Korlym |
| Corium, LLC | $22.17 | 2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $14.81 | 2025 | |
| Allergan, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Barter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.